Starch-processing and wet-milling plants, sweetener and syrup producers, brewers, distillers and bioethanol producers all buy the same class of biocatalyst for one purpose: converting starch drawn from corn, wheat and cassava into fermentable or food-grade sugar. Alpha-amylase, beta-amylase and glucoamylase do most of that conversion work, breaking starch chains into glucose, maltose and other simple sugars before the material moves on to fermentation, sweetener refining or feed formulation.
Contrive Datum Insights has published "Starch Sugar Enzymes Market Size, Share & Industry Analysis, By Type (Alpha Amylase, Beta Amylase, Glucoamylase, Other), Application (Industrial, Specialty, Other), Source (Microbial, Plant, Animal), End-use industry (Food & Beverage, Biofuel & Ethanol, Animal Feed, Other), Form (Liquid, Dry/Powder), and Regional Forecast, 2026-2034." The study values the global market at USD 4.2 billion in 2025, rising to USD 4.48 billion in 2026 and reaching USD 7.64 billion by 2034, a compound annual growth rate of 6.9% across the forecast period.
Spending Concentrates in Glucoamylase and Food and Beverage Demand
Within the type axis, glucoamylase draws the largest share of buyer spending: 44% of 2025 revenue, worth USD 1.848 billion, expanding to 46% by 2034. Alpha-amylase holds a smaller position, 33% of 2025 revenue, and grows more slowly than the market overall, at 6.15%. Other formulations, a smaller category today, expand fastest at 8.16% a year, lifting their share of revenue from 9% to 10% and their value from USD 0.378 billion to USD 0.764 billion. That shift tracks a wider change in buyer demand: food and beverage manufacturers scaling up production of high-fructose corn syrup and glucose-based sweeteners, a trend the study rates as a high-impact driver of the market's growth.
The same pattern of concentrated demand appears on the other axes buyers segment along. Industrial applications account for 68% of 2025 revenue (USD 2.856 billion); specialty applications, a much smaller base, grow fastest, at 9.15%. Microbial sources dominate the raw-material side at 91% of 2025 revenue (USD 3.822 billion). Food and beverage end-use leads at 58% of 2025 revenue (USD 2.436 billion), though biofuel and ethanol buyers expand fastest, at 8.98%. Liquid formulations account for 72% of 2025 revenue (USD 3.024 billion); dry and powder forms grow faster, at 7.7%.
Buying activity concentrates regionally too. Asia Pacific holds 42% of 2025 revenue (USD 1.764 billion) and is forecast to reach 46% by 2034 (USD 3.514 billion) as regional starch-processing and bioethanol capacity expands. The United States is the single largest country market, at USD 0.964 billion in 2025, close to a quarter of global revenue (22.95%). Middle East and Africa stays the smallest region throughout, moving from 4% of revenue in 2025 to 5% by 2034.
Contrive Datum Insights sets that 6.9% base-case rate inside a range. If bioethanol capacity additions and enzymatic-process adoption in Asia Pacific move faster than expected, 2034 revenue could reach USD 8.66 billion. If feedstock costs rise and buyers substitute toward alternative sweeteners sooner than assumed, growth would instead settle near USD 6.77 billion. Under either scenario, demand for starch-derived sugar keeps expanding through 2034, anchored by the food and beverage buyers who already account for more than half the market. The report is delivered as a PDF, and a free sample is available on request.